<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195789</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0859</org_study_id>
    <nct_id>NCT04195789</nct_id>
  </id_info>
  <brief_title>Assessment of Interstitial Lung Disease in Rheumatoid Arthritis by Lung Ultrasound</brief_title>
  <acronym>PO-PID</acronym>
  <official_title>Assessment of Interstitial Lung Disease in Rheumatoid Arthritis by Lung Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The high resolution chest scan is the gold standard for the screening of interstitial lung
      disease, but this remains an onerous examination, and irradiating.

      Ultrasound could be used to detect these disorders with a very good sensitivity and
      specificity. This exam offers the advantage of being non radiating, inexpensive, and
      accessible to the rheumatologist who already uses it in their daily practice.

      The investigators want to assess the lung ultrasound performance compared with the gold
      standard.

      Patients will be included during a regular follow-up consultation with their referent
      rheumatologist. If there is an indication of first line biotherapy or targeted therapy the
      doctor will propose to the patient to participate in the study, give him the information
      leaflet, collect orally non-opposition, and will complete a survey for evaluation of the
      general health and potential risk factors for interstitial lung.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensibility and specificity of the lung sonography for interstitial lung disease screening in rheumatoid arthritis patients.</measure>
    <time_frame>Month 12</time_frame>
    <description>To estimate the sensitivity and specificity of pulmonary ultrasound compared to CT scans in patients with rheumatoid arthritis consulting at the Lyon South Hospital Centre or the Edouard Herriot Hospital for the start-up of biotherapy or targeted therapy. (CT : computerized tomography)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Lung Diseases</condition>
  <condition>Lung Diseases, Interstitial</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sample population</arm_group_label>
    <description>Patients with Rheumatoid Arthritis consultant for the start of a biotherapy or targeted therapy agreeing to participate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lung sonography</intervention_name>
    <description>Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.
Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist.</description>
    <arm_group_label>Sample population</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  In routine care a blood test (blood count, platelets, ionogram, VS (velocity
           sedimentation), CRP (C reactive protein), liver test, BNP (B-type natriuretic peptide),
           electrophoresis of serum proteins, quantiferon, HIV serologies, HBV : hepatitis B virus
           , HCV: hepatitis C virus) will be performed on the day of inclusion visit (V0).

        -  Two more tubes of 4cc will be collected for a serum bank.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed for a rheumatoid arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women over the age of 18

          -  With rheumatoid arthritis meeting the criteria ACR (American College of Rheumatology)/
             EULAR (EUropean League Against Rheumatism) 2010

          -  Never received any biotherapy or targeted therapy

          -  Having an indication of introduction of biotherapy or therapy targeted (JAK
             inhibitors) (JAK : Janus kinase)

        Exclusion Criteria:

          -  Refusal to participate in the study

          -  Known pulmonary disease that can alter lung interstitium: cardiac decompensation, COPD
             (chronic obstructive pulmonary disease), thoracic surgery, infection pulmonary

          -  Patient with respiratory functional signs suggestive of PID (Diffuse interstitial lung
             disease)

          -  Patient with signs of cardiac decompensation

          -  Patient with pulmonary auscultation suggestive of PID

          -  Pregnant or lactating woman

          -  Psychiatric pathology seriously hindering understanding

          -  Difficulty understanding oral French

          -  Person deprived of liberty or under legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Muriel PIPERNO, MD</last_name>
    <phone>4 78 86 12 31</phone>
    <phone_ext>+33</phone_ext>
    <email>muriel.piperno@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cyrille CONFAVREUX, MD, PHD</last_name>
    <phone>4 72 67 88 83</phone>
    <phone_ext>+33</phone_ext>
    <email>cyrille.confavreux@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Rhumatologie. Centre hospitalier Lyon Sud. 69310</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Muriel PIPERNO, MD</last_name>
      <phone>4 78 86 12 31</phone>
      <phone_ext>+33</phone_ext>
      <email>muriel.piperno@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cyrille CONFAVREUX, MD,PHD</last_name>
      <phone>4 72 67 88 83</phone>
      <phone_ext>+33</phone_ext>
      <email>cyrille.confavreux@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Muriel PIPERNO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

